Navigation Links
PTC Therapeutics Reports Second Quarter Financial Results and Provides Corporate Update
Date:8/7/2014

SOUTH PLAINFIELD, N.J., Aug. 7, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and reported financial results for the second quarter ended June 30, 2014.

"This has been an exciting quarter for PTC. In May we received a positive opinion from the CHMP for marketing approval for Translarna™ (ataluren) an investigational new drug in the US, for nonsense mutation Duchenne muscular dystrophy and we recently received the approval from the European Commission granting the conditional marketing authorization. It is an honor to bring the world's first therapy for Duchenne muscular dystrophy to patients who have been waiting too long for a treatment. We are actively focused on providing Translarna to patients as quickly as possible and are working aggressively to prepare for launch across the EU," stated Stuart W. Peltz, Ph.D., Chief Executive Officer, PTC Therapeutics, Inc. "In addition to our efforts in nmDMD, we recently initiated our confirmatory Phase 3 clinical trial in nonsense mutation cystic fibrosis and it is our goal to initiate a Phase 2 proof-of-concept study for Translarna in a new indication, MPS I caused by a nonsense mutation, later this year. We expect the second half of the year will be a transformative time at PTC, as we expand our global commercial organization focused on our mission of bringing new therapies to patients with rare and neglected disorders."

Corporate Highlights:

  • ACT DMD: The confirmatory Phase 3 ACT DMD (Ataluren Confirmatory Trial in DMD) trial of Translarna™ (ataluren) in patients with nonsense mutation Duchenne muscular dystrophy (nmDMD) is well underway. Enrollment is expected to be completed near term with initial, top-line data available in the second half of 2015.
  • ACT CF: In June, the confirmatory Phase 3 ACT CF clinical trial was initiated. This tr
    '/>"/>

  • SOURCE PTC Therapeutics, Inc.
    Copyright©2014 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related medicine technology :

    1. Pivotal Therapeutics To Explore Potential Commercial Partnership Opportunities in China
    2. Relmada Therapeutics, Inc. Completes Name Change and Announces New Ticker
    3. PTC Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
    4. Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014
    5. Orexigen Therapeutics to Host Second Quarter 2014 Financial Results Conference Call and Webcast
    6. Lightlake Therapeutics Inc. Receives Funding Commitment From A Prominent International Research And Development Foundation
    7. Abide Therapeutics Appoints Nancy Thornberry to Board of Directors
    8. PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2014 Financial Results
    9. Lightlake Therapeutics Inc. Files Investigational New Drug Application For Naloxone Nasal Spray For Reversing Opioid Overdose And Announces A Further Collaboration With The National Institute On Drug Abuse
    10. Particle Sciences and Eyeon Therapeutics Receive Patent on Novel Dry Eye Technology
    11. MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/15/2014)... , December 15, 2014 ... Am 19. und 20. Februar sind ... Aegate SAFE MEDICINE ECOSYSTEM PARTNER PROGRAMM ™ ... zu besuchen. Diese Tagung soll ... die Möglichkeit geben, die neue profitablen Unternehmensdienstleistungen, ...
    (Date:12/15/2014)... DUBLIN , Dec. 12, 2014 Research and ... ( http://www.researchandmarkets.com/research/ms3j8c/cardiac ) has announced the ... Estimates and Forecasts, 2012-2018"  report to their offering. ... by 2016. The North America ... while Europe claims approximately 25% ...
    (Date:12/15/2014)... BRIDGEWATER, N.J. , Dec. 15, 2014 /PRNewswire/ ... (EURONEXT: SAN and NYSE: SNY) are collaborating with nationally-recognized ... Cholesterol Counts , an awareness program that will gauge ... the risks associated with high LDL-C (bad cholesterol).  American ... to take a brief poll and answer a ...
    Breaking Medicine Technology:Symposium über Aegates Ecosystem-Partner-Programm für sichere Medikamente vom 19. - 20. Februar 2015 in Amsterdam 2Cardiac Guidewires - Global Trends, Estimates and Forecasts, 2012-2018 2Cardiac Guidewires - Global Trends, Estimates and Forecasts, 2012-2018 3Cardiac Guidewires - Global Trends, Estimates and Forecasts, 2012-2018 4Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 2Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 3Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 4Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 5Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 6
    (Date:12/19/2014)... TX (PRWEB) December 19, 2014 ... a shifting, capital equipment market that is saturated ... impressive safety and efficacy as well as non-invasive ... they were first introduced to the healthcare market. ... the development of MRI safe technologies have greatly ...
    (Date:12/19/2014)... From November 24, 2014, Siddhi Yoga ... 2014 in its Goa retreat . This is the ... winters, from November to March, Siddhi Yoga will organize four ... Goa. The Goa training sessions will conclude in March 2015. ... training, the 10th intake is also a 200 YTT ...
    (Date:12/19/2014)... Wilmington, VT (PRWEB) December 19, 2014 ... full-service private ski club in Southern Vermont’s Deerfield Valley, ... trail names inspired by classic rock songs. , ... the weekend with a private concert followed by a ... said, “The new trail names include: “I’m Alright” the ...
    (Date:12/19/2014)... HealthDay Reporter THURSDAY, ... ibuprofen, might slightly reduce your risk of developing a ... ibuprofen (Advil, Motrin) and naproxen (Aleve) appear to reduce ... percent, the researchers concluded after reviewing nine prior studies. ... exposure. These painkillers "have potential as ...
    (Date:12/17/2014)... 17, 2014 Dr. Myo Nwe is the ... Diet of the Future” and co-founder of the Ace Medical ... Dr. Nwe takes a broad look at the industry of ... under scientific scrutiny. On film and in television shows, however, ... toward the social aspects and played for basic laughs, which ...
    Breaking Medicine News(10 mins):Health News:Magnetic Resonance Imaging Systems Market Analysis and Forecast to 2020 Report at RnRMarketReserach.com 2Health News:Magnetic Resonance Imaging Systems Market Analysis and Forecast to 2020 Report at RnRMarketReserach.com 3Health News:Magnetic Resonance Imaging Systems Market Analysis and Forecast to 2020 Report at RnRMarketReserach.com 4Health News:Siddhi Yoga’s 10th intake of YTT started in Goa on November 24, 2014 2Health News:Siddhi Yoga’s 10th intake of YTT started in Goa on November 24, 2014 3Health News:The Hermitage Club Officially Names Four Ski Trails after Iconic Rock Songs by Grammy Award Winner Kenny Loggins 2Health News:Common Painkillers May Help Prevent Certain Skin Cancers, Study Finds 2Health News:Common Painkillers May Help Prevent Certain Skin Cancers, Study Finds 3Health News:Obesity Should Not Be a Hollywood Punchline, Weight Loss Doc Says 2
    ... ... heart function without need for cardiac stem cells , ... (Vocus) July 16, 2009 -- Injured heart tissue normally can,t regrow, ... heart tissue after a heart attack, in patients with heart failure, or in children with ...
    ... coronary function are restored , THURSDAY, JULY 23 (HealthDay ... tissue renew itself after a heart attack -- until now. ... to the heart become blocked, preventing enough oxygen from getting ... But researchers at Children,s Hospital Boston report progress toward someday ...
    ... , , PIPERSVILLE, Pa., July 23 ... the body,s mechanism for cooling itself is overactive and can cause ... than normal. While some people may only think about sweating during ... can disrupt their daily and recreational activities, regardless of the season. ...
    ... , ROANOKE, Va., July 23 Job ... The Virginia Psychological Association (VPA) and Virginia Academy of Clinical ... this cost by awarding the 2009 VPA/VACP Psychologically Healthy Workplace ... submit nominations. , , ...
    ... , , LOS ANGELES, July 23 ... AIDS Programs and Policy is launching its most comprehensive community outreach campaign ... of those who have HIV does not know it. , ... Titled "Virus," the multi-faceted campaign is designed to raise doubt ...
    ... , INDIANAPOLIS, July 23 Today, Eli ... the U.S. Food and Drug Administration (FDA) has approved a ... injection] to treat osteoporosis associated with sustained, systemic glucocorticoid therapy ... therapy is the most common cause of secondary osteoporosis, leading ...
    Cached Medicine News:Health News:Study in this Week's Issue of Cell Finds Injected Growth Factor Spurs Heart Regeneration 2Health News:Study in this Week's Issue of Cell Finds Injected Growth Factor Spurs Heart Regeneration 3Health News:Injection May Heal Damaged Heart 2Health News:Photos: Don't Let Them See You Sweat This Summer 2Health News:Photos: Don't Let Them See You Sweat This Summer 3Health News:Photos: Don't Let Them See You Sweat This Summer 4Health News:Photos: Don't Let Them See You Sweat This Summer 5Health News:Los Angeles County Launches Its Most Comprehensive Campaign Ever to Encourage HIV Testing 2Health News:Los Angeles County Launches Its Most Comprehensive Campaign Ever to Encourage HIV Testing 3Health News:FDA Approves Expanded Use of Lilly's FORTEO(R) [teriparatide (rDNA origin) injection] to Treat Glucocorticoid-Induced Osteoporosis 2Health News:FDA Approves Expanded Use of Lilly's FORTEO(R) [teriparatide (rDNA origin) injection] to Treat Glucocorticoid-Induced Osteoporosis 3Health News:FDA Approves Expanded Use of Lilly's FORTEO(R) [teriparatide (rDNA origin) injection] to Treat Glucocorticoid-Induced Osteoporosis 4Health News:FDA Approves Expanded Use of Lilly's FORTEO(R) [teriparatide (rDNA origin) injection] to Treat Glucocorticoid-Induced Osteoporosis 5Health News:FDA Approves Expanded Use of Lilly's FORTEO(R) [teriparatide (rDNA origin) injection] to Treat Glucocorticoid-Induced Osteoporosis 6
    ... A surgically implanted bone growth stimulator ... EBI OsteoGen surgically implanted bone growth stimulator ... of nonunions when surgery is already planned ... concern. Because the OsteoGen is totally surgically ...
    ... contact between grant material and fracture ends ... bones., ,Grid-Like Format of Mesh Cathode Provides ... , ,The innovative Mesh Cathode of the ... and a scaffolding effect designed to increase ...
    ... Cystoscope System using EndoSheath Technology introduces ... urologists in both their hospitals and ... flexible cystoscope with the sterile, protective ... procedures, while minimizing the costs of ...
    ... Plasma-CISE™ (wire electrodes) and Plasma-CUT™ ... devices that produce precise, consistent ... spread and Vapor sealing of ... The devices provide excellent results ...
    Medicine Products: